Nanjing, Dec. 7, 2021, Zenshine Pharmaceuticals Co., Ltd. (Zenshine) announced that NMPA (National Medical Products Administration) has approved its IND application of ZX-101A to proceed phase 1 clinical trial for the treatment in patients with advanced solid tumors. Phase 1 clinical trial of ZX-101A in the US is undergoing in patients with relapsed/resistant or refractory advanced hematologic malignancies (ClinicalTrials.gov: NCT04504708). New approval of IND in China indicates another milestone for ZX-101A as the treatment for patients with advanced malignancies.
ZX-101A is a next-generation of PI3Kδ/γ inhibitor with improved therapeutic window in pre-clinical models. Dual inhibition of PI3Kδ and γ by ZX-101A as the treatment of hematologic malignancies may synergistically exert through directly inhibiting PI3K signaling in malignant lymphocytes and enhancing anti-tumor immunity. ZX-101A has the potential to be the best-in-class medicine for blood cancers as well as the first-in-class immune-oncology treatment to certain solid tumors in combination with check point inhibitors.
About Zenshine Pharma
Zenshine Pharma is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.